Guided Therapeutics Stock Performance
| GTHP Stock | USD 0.19 0.03 18.75% |
Guided Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -0.95, which attests to possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Guided Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Guided Therapeutics is expected to outperform it slightly. Use Guided Therapeutics total risk alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Guided Therapeutics.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Guided Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent technical indicators, Guided Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 182 K | |
| Total Cashflows From Investing Activities | -14 K |
Guided |
Guided Therapeutics Relative Risk vs. Return Landscape
If you would invest 14.00 in Guided Therapeutics on September 1, 2024 and sell it today you would earn a total of 5.00 from holding Guided Therapeutics or generate 35.71% return on investment over 90 days. Guided Therapeutics is currently generating 1.6886% in daily expected returns and assumes 15.6988% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Guided, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Guided Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Guided Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Guided Therapeutics, and traders can use it to determine the average amount a Guided Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1076
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | GTHP | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.69 actual daily | 33 67% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Guided Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Guided Therapeutics by adding it to a well-diversified portfolio.
Guided Therapeutics Fundamentals Growth
Guided OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Guided Therapeutics, and Guided Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guided OTC Stock performance.
| Return On Asset | -0.63 | |||
| Operating Margin | (38.63) % | |||
| Current Valuation | 19.66 M | |||
| Shares Outstanding | 48.58 M | |||
| Price To Earning | 36.67 X | |||
| Price To Sales | 219.47 X | |||
| Revenue | 81 K | |||
| EBITDA | (837 K) | |||
| Cash And Equivalents | 446 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.43 M | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | (0.13) X | |||
| Cash Flow From Operations | (1.59 M) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 2.04 M | |||
| Retained Earnings | (125.47 M) | |||
| Current Asset | 1.86 M | |||
| Current Liabilities | 8.55 M | |||
About Guided Therapeutics Performance
Assessing Guided Therapeutics' fundamental ratios provides investors with valuable insights into Guided Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Guided Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Guided Therapeutics performance evaluation
Checking the ongoing alerts about Guided Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Guided Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
- Analyzing Guided Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guided Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Guided Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guided Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guided Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Guided Therapeutics' otc stock. These opinions can provide insight into Guided Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.